touchONCOLOGY joins Editorial Board Member Prof Antoinette Wozniak (UPMC Hillman Cancer Center, Pittsburgh, PA, USA) at WCLC 2021 to discuss her highlights of the conference this year.
What have been your particular highlights of the World Conference on Lung Cancer 2021?
Disclosures: Antoinette Wozniak has no financial or non-financial conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 2021 WCLC Annual Meeting.
Share this Video
Related Videos In Lung Cancer
Tarlatamab in pre-treated SCLC – DeLLphi-301 study: Luis Paz-Ares, EMSO 2023
The anticipated phase 2 data from the DeLLphi-301 study (NCT05060016), investigating the antitumor activity and safety of taralatamab administered at two doses in pre-treated small cell lung cancer (SCLC), were presented at this year’s EMSO meeting. To understand more about this investigational treatment and the results from the study we spoke with study investigator, Dr […]
Sunil Singhal, AACR 2023: Intraoperative molecular imaging as a tool in cancer surgery
Intraoperative molecular imaging enables surgeons to utilise a cancer specific fluorescent dye to improve cancer removal. In this touchONCOLOGY interview, we speak with Dr Sunil Singhal (University of Pennsylvania, Philadelphia, PA, USA) to discuss intraoperative molecular imaging, with focus on its application in lung cancer. The presentation entitled ‘Intraoperative molecular imaging of lung cancer: The […]
Gerard Zalcman, ESMO 2022: IFCT-1701 phase III trial, investigating nivolumab plus ipilimumab in advanced non-small cell lung cancer
First-line immunotherapy is a standard treatment for patients with advanced non-small cell lung cancer. Prof. Gerard Zalcman (Bichat Hospital, Assistance Publique-Hôpitaux de Paris; Institute of Cancer AP-HP Nord, Paris, France) joins touchONCOLOGY to discuss the IFCT-1701 phase III trial, investigating nivolumab plus ipilimumab, aiming to assess if 6-months nivolumab/ipilimumab duration was equivalent to continuation until progression […]